| Old Articles: <Older 43951-43960 Newer> |
|---|
 |
The Motley Fool
September 7, 2010
Rick Aristotle Munarriz |
7 Reasons Not to Worry This Week Not every company will be posting lower earnings this week. Some companies will offer better news.   |
The Motley Fool
September 6, 2010
Jesse Emspak |
ADC Looks to Settle Suits Ahead of Tyco Sale The telecommunications gear provider is hoping to clear legal hurdles ahead of its sale. |
The Motley Fool
September 6, 2010
Manikandan Raman |
Google, Apple Could Extend Battle on Musical Turf Google announces plans to launch its own music store -- a direct challenge to Apple's iTunes. |
The Motley Fool
September 4, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Morgan Stanley points out that Melco Crown Entertainment is 24% cheaper than it once was, and a company that may be even more than 24% better-positioned to reward investors, thanks to Macau. |
The Motley Fool
September 3, 2010
John Keeling |
Buy or Short These Industrial Stocks? Here are the top two and bottom two industrial companies in a quality of earnings screen of commercial services and supplies companies. |
The Motley Fool
September 3, 2010
John Keeling |
Buy or Short These Defense Technology Stocks? This earnings quality screen (and decade of corroborating evidence!) suggests that GenCorp and Ceradyne are buy candidates and Orbital Sciences and Alliant TechSystems might potentially be shorting opportunities. |
The Motley Fool
September 3, 2010
John Rosevear |
Autos Weekly: GM's New Anxiety New details emerge on GM's plan for going public. |
The Motley Fool
September 3, 2010
Seth Jayson |
Will DryShips Fumble Next Quarter? Is DryShips sending any warning signs for the next quarter? Take a look at this chart, which plots revenue growth against their accounts receivable growth and days sales outstanding. |
The Motley Fool
September 3, 2010
Jordan DiPietro |
This Is Still the Best Bank to Own Despite the fact that the sovereign debt crisis in Europe has faded slightly from the headlines, the risk is still out there. Let's evaluating European banks using several metrics. |
The Motley Fool
September 3, 2010
Brian Orelli |
Why You Just Got Hammered Celldex's decline is due to potential reasons Pfizer would send back a drug it's been working on with Celldex for over two years |
| <Older 43951-43960 Newer> Return to current articles. |
